Clinical Complications and Laboratory Disturbances Following Administration of Intravenous Immunoglobulin (IVIG) in hospitalized Children in Imam Hossein Hospital, Isfahan, Iran, in Years 2018-2019

Document Type : Original Article (s)

Authors

1 Assistant Professor, Department of Pediatrics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Department of Allergy and Clinical Immunology, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran

3 Student of Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Intravenous immunoglobulin (IVIG) is a product isolated from the plasma of donors. Laboratory variations are one of the complications of this product. The goal of this study was to evaluate the adverse effects and laboratory variations in children receiving IVIG.\Methods: This retrospective cross-sectional study was conducted by studying the file records of all admitted patients receiving IVIG in Imam Hossein Hospital, Isfahan, Iran, in years 2018-2019. Then, all registering data in collection form were entered into SPSS software, and relevant analysis was performed.Findings: Serum sodium, potassium, and hemoglobin reduced significantly. Blood urea nitrogen (BUN) level increased after infusion. However, changes in albumin and creatinine were not statistically significant. 3 patients (16.67%) developed fever, chills, and headache after infusion. No reduction in urinary output, or acute renal failure was observed in any of patients.Conclusion: The laboratory variations are not clinically dangerous in patients. Follow-up tests are not routinely recommended for all patients.

Keywords

References

  1. Arumugham VB, Rayi A. Intravenous Immunoglobulin (IVIG). In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2021.
  2. Bauhofer A, Schimo S, Klausmann M. Benefits of immunoglobulin substitution in primary and secondary immunodeficiencies: Interim analysis of a prospective, long-term non-interventional study. Int J Clin Pharmacol Ther 2021; 59(6): 417-27.
  3. Perez EE. Immunoglobulin use in immune deficiency and autoimmune disease states. Am J Manag Care 2019; 25(6 Suppl): S92-S97.
  4. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004; 2(9): 695-703.
  5. Chen Y, Wang C, Xu F, Ming F, Zhang H. Efficacy and tolerability of intravenous immunoglobulin and subcutaneous immunoglobulin in neurologic diseases. Clin Ther 2019; 41(10): 2112-36.
  6. Rutter A, Luger TA. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol 2001; 44(6): 1010-24.
  7. Sullivan KE, Stiehm ER. Stiehm's immune deficiencies. 2nd ed. London, UK: Elsevier Science; 2020.
  8. Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol 2018; 9: 1299.
  9. Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve 1997; 20(9): 1102-7.
  10. Kantar A, BASKIN E, Gulleroglu K, Kirnap M, Akdur A, Yildirim S, et al. SP900. Hyponatremia following intravenous immunoglobulin therapy in pediatric transplant recipients. Nephrol Dial Transplant 2015; 30(suppl_3): iii673.
  11. Daphnis E, Stylianou K, Alexandrakis M, Xylouri I, Vardaki E, Stratigis S, et al. Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy. Nephron Clin Pract 2007; 106(4): c143-c148.
  12. Dantal J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol 2013; 38(4): 275-84.
  13. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006; 6(4): 535-42.
  14. Seidling V, Hoffmann JH, Enk AH, Hadaschik EN. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events. Acta Derm Venereol 2013; 93(3): 346-9.
  15. Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology 2001; 62(3): 133-7.
  16. Dashti-Khavidaki S, Aghamohammadi A, Farshadi F, Movahedi M, Parvaneh N, Pouladi N, et al. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. J Investig Allergol Clin Immunol 2009; 19(2): 139-45.
  17. Carbone J. Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr Drug Saf 2007; 2(1): 9-18.
  18. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29(3): 173-84.
  19. Kareva L, Mironska K, Stavric K, Hasani A. Adverse reactions to intravenous immunoglobulins - our experience. Open Access Maced J Med Sci 2018; 6(12): 2359-62.

Files

History

  • Receive Date: 31 August 2021
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics